Kenvue Inc. is a consumer health company operating in the United States, the rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. Its product portfolio includes over-the-counter medicines for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as naturally inspired self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. The company sells its products under brands such as Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, Zyrtec, Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, Rogaine, BAND-AID, Carefree, Desitin, Johnson's, Listerine, o.b., Stayfree, ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson's Baby, Johnson's Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.
Kenvue's $40B Kimberly-Clark Deal Advances Through Regulatory and Debt Steps
◆
EU antitrust review moves forward with possible asset sales Kimberly-Clark asked EU regulators to approve the Kenvue deal and is preparing asset sales to ease competition concerns, with a key deadline on September 29. Approval would keep the deal on track, but forced divestitures could reduce the value Kenvue shareholders ultimately receive.
This is the main regulatory hurdle that determines whether the deal closes and on what terms.
▲
Kimberly-Clark launches exchange offers for Kenvue notes Kimberly-Clark offered to swap Kenvue's existing bonds into new Kimberly-Clark notes and asked bondholders to approve changes to debt rules. This simplifies the debt structure and moves Kenvue's obligations onto Kimberly-Clark's balance sheet, a concrete step toward closing the deal.
It shows the deal is moving into the financing and integration phase, reducing uncertainty for Kenvue shareholders.
▼
Kenvue's weak Q2 results and debt load add risk Kenvue's second-quarter adjusted earnings missed estimates, gross margin fell due to inflation, tariffs, and currency effects, and the company carries $8.5 billion in debt. These operational and financial challenges could weigh on the combined company's performance after the deal closes.
It highlights the underlying business weakness that could hurt Kenvue's value regardless of the deal outcome.
◆
Kimberly-Clark's dividend streak and balance sheet strength Kimberly-Clark raised its dividend for the 54th straight year, showing financial stability, but its stock is down 20% over the past year and it carries $6.5 billion in debt. A stronger acquirer supports deal completion, but its weak share price affects the value of the stock portion Kenvue holders will receive.
It reflects the acquirer's ability to complete the deal and the market's current view of the combined company.
Q3 2026
▲2▼2
Kenvue Buyout Advances, But Regulatory and Financial Risks Loom
▲
Shareholder Approval of Kimberly-Clark Buyout Kenvue shareholders approved Kimberly-Clark's $48.7 billion buyout, expected to create a defensive, high-margin company with $1.9–2.1 billion in cost savings. The deal also advanced via EU review and Kimberly-Clark's 54th straight dividend increase.
This is the central event of the quarter, directly affecting Kenvue's ownership and future prospects.
▼
Regulatory Hurdles in China and EU China escalated its antitrust probe to phase 2, and EU approval may require divestitures that could reduce shareholder value. These regulatory risks add uncertainty to the deal's completion and terms.
Regulatory setbacks can delay or alter the buyout, impacting Kenvue's stock price.
▼
Weak Q2 Results and Financial Pressures Kenvue's weak Q2 missed estimates amid inflation, tariffs, and currency headwinds, with $8.5 billion in debt. Kimberly-Clark's stock is down 20% and carries $6.5 billion in debt, affecting the stock portion Kenvue holders receive.
Poor financial performance and high debt levels weigh on investor sentiment and the value of the buyout consideration.
▲
FDA Approval of Tylenol with Naproxen The FDA approved Tylenol with Naproxen, expanding Kenvue's product lineup and potentially boosting future sales. This positive development offers a counterweight to the regulatory and financial challenges.
New product approval can drive growth and partially offset negative pressures.
News & notes movingKVUE
United States
KVUE
Kimberly-Clark Launches Exchange Offers for Kenvue Notes
Kimberly-Clark has launched exchange offers and consent solicitations for Kenvue's outstanding notes tied to its pending acquisition of the company. The proposal gives Kenvue bondholders the option to swap existing securities into new Kimberly-Clark issued notes on specified terms, and the consent solicitations seek bondholder approval to amend certain covenants in Kenvue's current debt documents as part of the transaction process. The exchange offers include new Kimberly-Clark notes plus cash and early participation premiums, effectively asking bondholders to accept Kimberly-Clark as the primary borrower on refreshed terms. Kimberly-Clark, a US household products manufacturer with a market value of about $32.9b, is seeking to simplify the debt structure around the pending Kenvue acquisition and bring those obligations directly onto its own balance sheet. The clearest early sign of success will be the level of noteholder participation and whether Kimberly-Clark secures the majority consents needed to strip restrictive covenants from the Kenvue indenture.
KMB · Capital · Neutral Kimberly-Clark launches exchange offers and consent solicitations to move Kenvue's notes onto its own balance sheet as part of the pending acquisition.
KVUE · Capital · Neutral Kenvue bondholders are offered swaps into new Kimberly-Clark notes and asked to approve covenant amendments tied to Kimberly-Clark's pending acquisition of Kenvue.
Kimberly-Clark to Sell Assets Over $40 Billion Kenvue Deal EU Antitrust Concerns
Kimberly-Clark plans to sell assets tied to its planned US$40b acquisition of consumer products group Kenvue in order to address European Union antitrust concerns. The disposals target overlaps in consumer health and personal care brands, with asset sale discussions focused on EU markets where regulators flagged competition issues during their ongoing review of the Kenvue deal. Kimberly-Clark, a US household products group with a market cap of about US$32.6b, earns its money from personal care brands that sit close to Kenvue's consumer health and hygiene lines, which is exactly where regulators are probing for competitive overlap in Europe. The planned Kenvue acquisition, together with the targeted EU disposals, pushes Kimberly-Clark closer to Procter & Gamble and Colgate-Palmolive in terms of breadth, while the asset sales suggest management is prepared to trim overlap to keep the deal on track. Selling brands to satisfy regulators may reduce competitive pressure, but it also shrinks the pool of potential synergies and places more weight on flawless integration and disciplined marketing to maintain pricing power.
KMB · Regulation · Neutral Kimberly-Clark plans EU asset sales to address antitrust concerns over its $40B Kenvue acquisition, trimming overlap but reducing synergies.
KVUE · Regulation · Neutral Kenvue is the acquisition target whose deal faces EU antitrust review, prompting Kimberly-Clark's planned asset disposals.
AI Stocks Plunge, 10-Year Treasury Yield Tops 5%, Oil Surges Over 4%
Wall Street traded lower on Monday as AI-related shares tumbled after executives at leading U.S. AI companies called for a slower pace of development, with SoftBank falling as much as 13.2% in Japan, SK Hynix dropping 6.4%, Samsung Electronics declining 4%, and in the U.S. Nvidia slipping 2.4% premarket while Micron and AMD each fell 5% and Broadcom dropped 3.4%, following an essay Saturday by Anthropic CEO Dario Amodei arguing that progress on improving AI model capabilities should be slowed. Crude oil surged, with front-month Nymex crude jumping 4.3% to $104.37/bbl and Brent rising 4.5% to $109.32/bbl, after Persian Gulf countries called off a planned meeting with Iran on reopening the Strait of Hormuz and a Friday drone strike knocked out Saudi Arabia's East-West pipeline, which feeds the Red Sea port of Yanbu and moves 4M bbl/day; traders estimate the closure could cut off up to 4% of global oil supply, with Yanbu storage covering just 5-7 days of exports. The benchmark 10-Year Treasury yield reached 5% for the first time since October 23, 2023, adding 3 basis points Monday, while the 2-Year yield rose 4 basis points to about 4.66% and the 30-Year added 2 basis points to 5.37%. Kimberly-Clark is preparing possible asset sales to resolve European Union competition concerns over its proposed $40 billion acquisition of Kenvue, with the European Commission expected to notify the company of its concerns this week ahead of a preliminary review deadline on September 29.
000660.KO · Technology · Negative SK Hynix dropped 6.4% amid the AI-related selloff following calls to slow AI model development.
005930.KO · Technology · Negative Samsung Electronics declined 4% as AI-related shares tumbled on calls to slow AI development.
9984.JP · Technology · Negative SoftBank fell as much as 13.2% in Japan as AI-related shares tumbled on calls to slow AI development.
NVDA · Technology · Negative Anthropic CEO's call to slow AI development drove AI-related shares lower, with Nvidia slipping 2.4% premarket.
KMB · Regulation · Negative Kimberly-Clark may need asset sales to resolve EU competition concerns over its $40B Kenvue acquisition, with the Commission set to notify concerns.
KVUE · Regulation · Neutral Kenvue is the target of Kimberly-Clark's $40B acquisition facing EU competition concerns, but no direct impact on Kenvue is stated.
Sorbent to acquire Kenvue's Stayfree and Carefree ANZ business
Sorbent Paper Company Pty Ltd has signed an agreement with Kenvue's Singaporean subsidiary to acquire its Stayfree and Carefree feminine care business in Australia and New Zealand. Following completion of the transaction, the New Zealand portion of the business will be managed by Sorbent's affiliate, Cottonsoft. The acquisition marks Sorbent and Cottonsoft's entry into the feminine hygiene category and represents a further step in their strategy to strengthen their positions in the consumer tissue category while expanding their portfolios through established consumer brands in adjacent categories. The transaction is subject to regulatory approval in Australia and New Zealand and other customary closing conditions, as well as the completion of the Kimberly-Clark and Kenvue transaction. Financial terms of the transaction have not been disclosed.
Sorbent Paper Company Pty Ltd · Capital · Positive Sorbent signed an agreement to acquire Kenvue's Stayfree and Carefree ANZ business, expanding into feminine hygiene.
KVUE · Capital · Positive Kenvue is divesting its Stayfree and Carefree ANZ feminine care business to Sorbent, a portfolio-slimming M&A move.
Cottonsoft · Capital · Positive Cottonsoft, Sorbent's affiliate, will manage the New Zealand portion of the acquired Stayfree and Carefree business.
Kimberly-Clark has extended its dividend increase streak to 54 consecutive years with its Q2 2026 declaration, even as it works to close a $48.7 billion acquisition of Kenvue by the end of 2026. The board raised the quarterly payout to $1.28 per share, up from $1.26 in late 2025 and $1.22 in 2024, for an annualized forward dividend of $5.12, with the next payment scheduled for October 2, 2026. Kimberly-Clark enters the transition with $956 million in cash and total debt of roughly $6.52 billion as of June 30, 2026, while full-year 2025 operating cash flow of $2.777 billion covered $1.138 billion of capex and $1.66 billion of dividends before any Kenvue-related financing. CEO Mike Hsu called the transaction a powerful next step in the company's transformation and a unique, generational value creation opportunity, and management said roughly 50 teams and 600 people are working on synergy planning. Q2 2026 adjusted EPS of $2.12 beat the $2.01 estimate and adjusted gross margin expanded 190 basis points to 38.8%, but the stock is down 20.36% over the past year to $98.15, pushing the yield near 5.16%.
KMB · Capital · Positive Kimberly-Clark raised its quarterly dividend to $1.28, extending its 54-year streak, while also beating Q2 EPS estimates with margin expansion.
KVUE · Capital · Neutral Kenvue is the target of Kimberly-Clark's $48.7 billion acquisition, with the deal still pending close by end of 2026.
Kimberly-Clark Seeks EU Approval for $40 Billion Kenvue Deal
Kimberly-Clark has requested European Union permission for its proposed $40 billion takeover of Kenvue, moving the transaction into another stage of regulatory review. The deal, first announced in November 2025, would combine Kimberly-Clark with consumer-health brands including Tylenol, Listerine, Aveeno, and Neutrogena, creating a company with roughly $32 billion in annual revenue and projected annual cost savings of $2.1 billion. The EU filing is a request for clearance, not an approval, and does not indicate when a decision will come or whether conditions may be imposed. Kimberly-Clark originally expected the deal to close in the second half of 2026, but that remains a forecast. The company faces execution risks from integrating two large businesses and delivering the projected savings, which represent about 6.6% of the combined revenue.
Kenvue-Kimberly-Clark Deal Nears Closing With Risks Ahead
Kenvue Inc. is moving closer to its planned combination with Kimberly-Clark Corporation, with shareholder approvals secured and the U.S. antitrust waiting period expired, though the cash-and-stock transaction is expected to close in the fourth quarter of 2026, subject to remaining foreign regulatory approvals and customary conditions. Kenvue shareholders are expected to receive 0.14625 Kimberly-Clark shares plus $3.50 in cash for each Kenvue share, and they are expected to own about 46% of the combined company on a fully diluted basis after closing. Kimberly-Clark has announced a post-closing organizational structure, but Kenvue is not providing forward-looking financial guidance while the deal is pending, and expected benefits may not be realized. Recent results show execution challenges: second-quarter 2026 net sales rose 3% to $3,955 million and organic sales increased 1.6%, but adjusted earnings of 31 cents per share missed the Zacks Consensus Estimate of 32 cents, while adjusted gross margin fell 70 basis points to 60.2% due to inflation, tariffs, and unfavorable transactional foreign exchange. Self Care remains a pressure point with first-half organic sales down 0.9%, while Skin Health and Beauty provided a stronger offset with organic sales up 4.4% and segment adjusted operating income rising 46.9% to $354 million. The balance sheet adds risk: Kenvue had $8.5 billion of total debt and $1.1 billion of cash as of June 28, 2026, and the 2026 restructuring program is expected to carry approximately $250 million of pre-tax charges before delivering approximately $200 million of annualized pre-tax gross cost savings. Legal and macro pressures persist, including the Second Circuit vacating the prior acetaminophen judgment in July 2026 and remanding the litigation, talc-related liabilities outside the U.S. and Canada, and annualized gross tariff exposure estimated at approximately $80 million. Major milestones are complete, but the expected fourth-quarter closing still carries regulatory, operational, and financial risk.
KVUE · Capital · Negative Q2 adjusted EPS missed estimates, gross margin fell due to inflation, tariffs, and FX; debt and restructuring charges add risk.
KMB · Capital · Neutral Merger nearing close with risks; deal expected to close Q4 2026, but benefits may not be realized.
Essity to acquire Kenvue's feminine care business in Brazil for USD 284m
Essity has agreed to acquire Kenvue's feminine care business in Brazil, including the market-leading brands Carefree, Sempre Livre and o.b., for USD 284m on a cash and debt-free basis. The acquisition is structured as an asset purchase from certain Kenvue subsidiaries and includes ownership of the brands for sanitary pads, liners and tampons, as well as related manufacturing equipment in Brazil. For the twelve-month period ending June 30, 2026, the acquired business had net sales of approximately BRL 800m with good profitability. The transaction is subject to regulatory approval in Brazil and other customary closing conditions, as well as the completion of the Kimberly-Clark and Kenvue transaction, and is expected to close during the second quarter of 2027. Essity says the acquisition strengthens its position as a market leader in feminine care in Latin America and marks another step in its strategy to grow in its most value-creating categories.
China antitrust regulator deepens review of Kimberly-Clark Kenvue deal
China's State Administration for Market Regulation has moved its evaluation of Kimberly-Clark's planned $49 billion acquisition of Kenvue into a phase 2 review, according to traders citing a Capitol Forum report. The deal was expected to have a quick review, but a complaint by an antitrust expert at Beijing's Tsinghua University and a safety controversy involving Kimberly-Clark and other diaper makers may have triggered the in-depth review. The transaction, announced in January, is expected to close in the second half of 2026 and would create a projected $32 billion revenue health and wellness leader. Shares of Kimberly-Clark advanced 1.3% on Wednesday, while Kenvue rose 1.1%.
Kimberly-Clark's 54-Year Dividend Streak and Kenvue Deal Draw Income Investor Attention
Kimberly-Clark raised its quarterly dividend from $1.26 to $1.28 per share in January 2026, bringing the annual payout to $5.12 per share and a yield of about 4.6% with the stock near $110. The company has increased its dividend for 54 consecutive years and paid dividends for 92 years, supported by essential brands like Huggies, Kleenex, and Scott that hold No. 1 or No. 2 positions in roughly 70 countries. Cash from operations including discontinued operations reached $1.7 billion in the first half of 2026, up from $1.1 billion a year earlier, while capital spending rose to $776 million from $401 million and dividends paid totaled $843 million. Management expects about $2 billion in adjusted free cash flow for 2026, roughly in line with 2025, despite plans to spend about $1.3 billion on capital investments. The pending Kenvue acquisition, expected to close in the fourth quarter of 2026, is projected to add about $1.9 billion in cost synergies and another $500 million in profit from revenue synergies within three to four years of closing, though integration risks remain.
Kenvue misses quarterly estimates as inflation and tariffs squeeze margins
Kenvue narrowly missed Wall Street estimates for second-quarter results as inflation, tariffs, and currency-related costs squeezed margins. Adjusted gross margin fell to 60.2% from 60.9% a year earlier, while adjusted profit came in at 31 cents per share, just below the 32-cent analyst estimate. Quarterly sales rose 3% to $3.96 billion, slightly missing the $3.97 billion consensus. The consumer-health company, currently in the midst of a $40 billion buyout by Kimberly-Clark, expects the deal to close in the fourth quarter of 2026.
Kenvue's Brand Strength and Growth Drivers Shape Its Future Outlook
Kenvue Inc. remains a closely watched consumer health name as investors weigh trusted brands, improving margins and a major pending transaction. In the first quarter of 2026, adjusted gross margin expanded 80 basis points to 60.8% and adjusted operating margin improved 420 basis points to 24%, driven by supply-chain productivity and cost optimization actions. Skin Health and Beauty net sales increased 8.4%, with organic sales up 5%, supported by volume growth and innovation such as Neutrogena's entry into sun care in select EMEA markets. The pending cash-and-stock combination with Kimberly-Clark Corporation, under which Kenvue shareholders are expected to receive 0.14625 Kimberly-Clark shares plus $3.50 in cash per Kenvue share, has received shareholder approvals and U.S. antitrust clearance, with closing expected in the second half of 2026. The stock currently carries a Zacks Rank #3 (Hold), with Value, Growth and VGM Scores of C and a Momentum Score of D, reflecting a balanced near-term view.
KVUE · Capital · Positive Improved margins (gross +80bps, operating +420bps) and pending acquisition by Kimberly-Clark with shareholder and antitrust approvals.
KMB · Capital · Positive Pending combination with Kenvue is a strategic M&A transaction that expands Kimberly-Clark's consumer health portfolio.
Kenvue Increases Quarterly Cash Dividend to $0.21 Per Share
Kenvue declared a quarterly cash dividend of $0.21 per share, a 1.2 percent increase from the prior quarterly dividend. The dividend is payable on August 26, 2026, to shareholders of record as of the close of business on August 12, 2026.
FDA Approves Tylenol With Naproxen, Boosting Kenvue's Self Care Portfolio
Kenvue received FDA approval for Tylenol with Naproxen, a new over-the-counter pain reliever offering up to 12 hours of pain relief and slated for distribution across major U.S. retailers. The approval adds a differentiated option to Kenvue's Self Care portfolio and could strengthen the Tylenol brand's position in the competitive pain relief category. The company's upcoming second quarter 2026 results on August 6, 2026, will provide an updated view on Self Care performance and how quickly new launches like Tylenol with Naproxen contribute alongside existing brands. Kenvue's investment narrative projects $16.7 billion revenue and $2.3 billion earnings by 2029, with a fair value estimate of $19.50 per share. Community valuations for Kenvue range from $19.50 to $32.38 per share, reflecting divergent expectations about the impact of new products on the company's growth trajectory.
FDA Clears Kenvue's TYLENOL With Naproxen, First OTC Fixed-Dose Combination
The FDA has approved Kenvue's TYLENOL with Naproxen, the first and only over-the-counter fixed-dose combination of acetaminophen and naproxen sodium for pain relief. The product combines 650 mg of acetaminophen with 220 mg of naproxen sodium, offering fast-acting relief in under 30 minutes and up to 12 hours of relief in a single dose. The approval is supported by eight clinical studies showing superior pain relief compared to either ingredient alone, and the FDA has granted three years of exclusivity. Kenvue plans to make the product available soon at major U.S. retailers nationwide.
Jim Cramer Says Kimberly-Clark’s Acquisition of Kenvue Creates a High-Margin Powerhouse
Jim Cramer highlighted Kimberly-Clark as a defensive holding on CNBC's Mad Money, citing its acquisition of Kenvue, Johnson & Johnson's former consumer health business. The deal adds brands like Tylenol, Neutrogena, Listerine, and Band-Aids, creating a high-margin powerhouse with steady cash flow through economic cycles. Kimberly-Clark trades at roughly 14 times earnings, near its lowest multiple in a decade, and offers a 4.74% dividend yield after raising its quarterly payout to $1.28 per share, backed by 54 consecutive years of dividend increases. Cramer sees the stock as a long-term opportunity with potential upside from the Kenvue integration, though he does not expect a blowout second-quarter report on August 4th. Institutional investors own about 93% of the company, while a 14.5% short float could fuel a squeeze if integration results beat expectations.
Kimberly-Clark's 54-Year Dividend Streak and Kenvue Deal Make It a Buy
Kimberly-Clark, a Dividend King with 54 consecutive years of dividend increases, offers a 4.7% yield and is positioned for solid returns following a strategic shift. The company recently formed a joint venture called Arbex with pulp supplier Suzano, offloading its lower-margin paper-towel and tissue business to focus on higher-margin personal-care products while retaining licensing royalties. This move frees up resources to integrate its pending acquisition of Kenvue, a consumer health company spun off from Johnson & Johnson in 2023, which Kimberly-Clark expects will generate approximately $1.9 billion in cost synergies and roughly $500 million in profit from revenue synergies within three to four years of closing. Analysts have a median price target of $113 per share, implying 5% upside, and the stock trades at 14 times earnings.
KMB · Capital · Positive Kimberly-Clark formed a JV to offload lower-margin business and expects $1.9B cost synergies and $500M profit from Kenvue acquisition, with a 4.7% yield and 54-year dividend streak.
KVUE · Capital · Positive Kenvue is being acquired by Kimberly-Clark, which expects significant synergies; the deal is pending and viewed positively.
Four Dividend Kings Are Crushing the S&P 500 in 2026 and Still Have Big Upside Potential
Four Dividend Kings are significantly outperforming the S&P 500's 9% gain in 2026 while offering reliable dividends backed by over 50 consecutive years of increases. Target surged 32% year to date and still trades at a cheap valuation with a 3.56% dividend yield. Colgate-Palmolive extended its 63-year dividend growth streak with a roughly 20.4% gain. Coca-Cola rose more than 16%, extending its 64-year dividend streak, and Kimberly-Clark advanced over 13% while yielding 4.41% and pursuing a $48.7 billion acquisition of Kenvue. All four stocks are rated Buy by top Wall Street firms.
Church & Dwight vs. Kimberly-Clark: Which Consumer Goods Stock Is a Better Buy in 2026?
Church & Dwight and Kimberly-Clark present contrasting investment cases in the household products market for 2026. Church & Dwight reported fiscal 2025 revenue of nearly $6.2 billion with a net margin of roughly 11.9%, while Kimberly-Clark posted revenue of nearly $17.2 billion and a net margin of roughly 11.7% despite a 14.2% revenue decline. Church & Dwight maintains a debt-to-equity ratio of roughly 0.6x and generated close to $1.1 billion in free cash flow, whereas Kimberly-Clark carries a debt-to-equity ratio of approximately 4.9x and generated nearly $1.6 billion in free cash flow. Kimberly-Clark is undergoing a transformation through its Arbex joint venture and the pending acquisition of Kenvue, while Church & Dwight focuses on seven power brands including Arm & Hammer and OxiClean. The author concludes that Church & Dwight offers a better balance of long-term growth and dividend income, though income-focused investors may prefer Kimberly-Clark.
CHD · Capital · Positive Article compares Church & Dwight favorably, highlighting strong margins, low debt, and free cash flow, concluding it is a better buy.
KMB · Capital · Negative Article notes Kimberly-Clark's 14.2% revenue decline and high debt-to-equity ratio, and concludes it is less attractive for growth.
KVUE · Capital · Neutral Kenvue is mentioned only as a pending acquisition target by Kimberly-Clark; no direct impact on Kenvue itself.
Illinois Appellate Court Affirms $45 Million Mesothelioma Verdict Against Johnson & Johnson and Kenvue
The Illinois Appellate Court has affirmed a $45 million jury verdict awarded to the family of Theresa Garcia, who died of mesothelioma after decades of using Johnson & Johnson's Baby Powder. The court rejected Johnson & Johnson's efforts to overturn the verdict or reduce the judgment, upholding the trial court's denial of the company's requests for judgment notwithstanding the verdict, a new trial, and its challenge to Illinois' prejudgment interest statute. The appellate court also upheld findings that Kenvue Inc. and Johnson & Johnson Holdco (NA), Inc. could be held liable as successors to Johnson & Johnson's former consumer products business despite corporate restructuring, and affirmed the jury's award for years of life lost under the Illinois Survival Act. The decision marks a significant appellate victory for asbestos victims and contradicts Johnson & Johnson's public assertions that adverse talc verdicts rarely survive appellate review.
Kimberly-Clark Outperforms S&P 500 and Nasdaq in 2026, Fueled by Recession Resistance and Kenvue Acquisition
Kimberly-Clark has risen 13.7% year to date, outpacing the S&P 500 and Nasdaq Composite, and offers a 4.5% dividend yield. The company’s recession-resistant portfolio of household brands like Huggies and Kleenex supports consistent demand, while management expects to recover input cost inflation and expand margins over time. A pending acquisition of consumer health company Kenvue, approved by shareholders, is set to close before year-end and is projected to deliver $2.1 billion in annual run rate synergies by the second year. Kimberly-Clark trades at 15.2 times consensus 2026 earnings estimates, well below its 10-year median price-to-earnings ratio of 21.9, and has raised its dividend for 54 consecutive years.
Two Dividend Kings—stocks with over 50 consecutive years of dividend increases—are highlighted as long-term buys. Payroll processor Automatic Data Processing, with 51 years of dividend growth, is trading more than 25% off its 2025 highs and offers a 2.7% yield, having raised its dividend through past recessions with unemployment as high as 14.8%. Consumer health company Kenvue, spun off from Johnson & Johnson in 2023, inherited Dividend King status and yields 4.3%, while paper products giant Kimberly-Clark, another Dividend King yielding 4.5%, is seeking regulatory approval to merge with Kenvue later this year. If the merger proceeds, Kenvue shareholders would receive $3.50 in cash and roughly one-seventh of a Kimberly-Clark share per Kenvue share, preserving the combined entity’s Dividend King status.
Three Healthcare Stocks Under $30 With Reaffirmed Guidance and Near-Term Catalysts
Three healthcare stocks trading under $30—Kenvue, Pfizer, and Viatris—offer value setups heading into the second half of 2026. Kenvue, the consumer health company behind Tylenol and Neutrogena, closed at $19.83 and is being acquired by Kimberly-Clark for $3.50 cash plus 0.14625 Kimberly-Clark shares, with shareholder approval secured and the deal expected to close in the second half of 2026. Pfizer trades at $24.32 with a 7.2% dividend yield and a forward P/E of 8, having reaffirmed full-year 2026 revenue guidance of $59.5 to $62.5 billion and adjusted EPS of $2.80 to $3.00, supported by a pipeline that includes roughly 20 pivotal trial starts this year. Viatris, at $16.70, carries a forward P/E of 7 and has three FDA PDUFA decisions due before year-end 2026, while management reaffirmed 2026 guidance and is executing a restructuring targeting $600 to $700 million in annualized cost savings. Each name carries risks including deal execution, patent cliffs, and generic pricing pressure, but all three have reaffirmed 2026 outlooks and identifiable catalysts.
Kenvue Stock May Be a Bargain Despite Mixed Valuation Signals
Kenvue stock has climbed 14.5% over the past month, but valuation metrics are split. A Discounted Cash Flow analysis estimates an intrinsic value of about $31.13 per share, implying the stock trades at roughly a 36.3% discount. However, Kenvue's price-to-earnings ratio of about 23.5 times is above the Personal Products industry average of roughly 18.7 times and above a model-implied fair P/E of about 21.3 times, suggesting overvaluation on an earnings basis. The planned $48.7 billion acquisition of Kenvue by Kimberly Clark adds deal execution and integration risk that may affect how investors price the stock.
Kimberly-Clark Plans $48.7 Billion Acquisition of Kenvue
Kimberly-Clark has announced a planned $48.7 billion acquisition of Kenvue, a deal that would integrate Kenvue into Kimberly-Clark's consumer products portfolio. Kenvue, which trades on the NYSE under the ticker KVUE, last closed at $19.33, with the stock up 2.8% over the past week and 11.4% over the past month. Over the past year the share price declined 3.2% and over three years it declined 15.0%. Investors are watching for updates on how the deal could affect Kenvue's operations, capital allocation, and brand priorities, as well as any guidance on margins, capital spending, and future capital returns.
Kenvue Shares Down 8.8% Over Past Year Amid Analyst Target Cuts
Kenvue Inc. shares are down 8.8% over the past year and up 10% year-to-date. On April 15th, Citi cut its share price target to $19 from $20 with a Neutral rating, citing margin risk and high oil prices. Barclays raised its target to $19 from $18 on March 6th with an Equal Weight rating, but reduced it to $18 on April 14th, also noting higher input costs. Billionaire Glenn Dubin's Highbridge Capital held 1.1 million shares in the fourth quarter of 2025 and maintained that position in the first quarter of 2026.
Kimberly-Clark’s dividend payout ratio has climbed near 80%, but the balance sheet tells a more reassuring story for income investors. The company paid $1.28 per share on July 2, 2026, extending its annual increase streak to 53 years, though free cash flow barely covered the dividend in fiscal 2025 at 0.99 times. However, shareholder equity jumped 79% to $1.502 billion in 2025 while total debt fell by $620 million, slashing the debt-to-equity ratio from 9.42 times to 4.86 times. In the first quarter of 2026, operating cash flow surged 128% year over year to $745 million, and adjusted earnings per share of $1.97 beat estimates. The pending $48.7 billion acquisition of Kenvue and a mid-2026 joint venture with Suzano are set to reshape the asset base, with management guiding for double-digit adjusted EPS growth.
Zacks Names Five Beauty Stocks to Buy for Second-Half 2026
Zacks Investment Research recommends five beauty and cosmetics stocks for a stable portfolio in the second half of 2026, all carrying a Zacks Rank of 1 (Strong Buy) or 2 (Buy). The picks are Estée Lauder, Helen of Troy, Nu Skin Enterprises, Kenvue, and Interparfums. Estée Lauder, the sole Strong Buy, is expected to see earnings grow 31.9% in its fiscal year ending June 2027, driven by its Profit Recovery and Growth Plan and digital expansion. Kenvue's earnings estimate has risen 5.5% over the past 60 days, with projected revenue growth of 3.2%. The other three companies face near-term revenue or earnings declines, but are supported by strategic initiatives such as portfolio optimization and channel expansion.
EL · Capital · Positive Zacks ranks Estée Lauder as Strong Buy with expected 31.9% earnings growth driven by Profit Recovery and Growth Plan and digital expansion.
KVUE · Capital · Positive Zacks ranks Kenvue as a Buy with earnings estimate up 5.5% over 60 days and projected revenue growth of 3.2%.
HELE · Capital · Neutral Zacks recommends Helen of Troy as a Buy despite near-term revenue/earnings declines, supported by strategic initiatives.
IPAR · Capital · Neutral Zacks recommends Interparfums as a Buy despite near-term revenue/earnings declines, supported by strategic initiatives.
NUS · Capital · Neutral Zacks recommends Nu Skin as a Buy despite near-term revenue/earnings declines, supported by strategic initiatives.
Hormel Foods Outperforms Consumer Staples Sector with 9.8% Year-to-Date Gain
Hormel Foods has returned 9.8% year-to-date, outperforming the average 8.2% gain of the Consumer Staples sector, which comprises 173 stocks and ranks 15th out of 16 Zacks sectors. The company holds a Zacks Rank of 2, or Buy, and its full-year earnings consensus estimate has risen 4.6% over the past quarter. Within its Food - Meat Products industry, which has lost an average of 2.5% this year, Hormel's performance is notably stronger. Kenvue, another Consumer Staples stock, has returned 9.9% year-to-date and also carries a Zacks Rank of 2, with its current-year EPS estimate up 5.3% over three months.
HRL · Capital · Positive Hormel Foods has a Zacks Rank of 2 (Buy) and its full-year earnings consensus estimate has risen 4.6% over the past quarter, indicating positive analyst sentiment and earnings outlook.
KVUE · Capital · Positive Kenvue also carries a Zacks Rank of 2 (Buy) and its current-year EPS estimate is up 5.3% over three months, reflecting positive analyst revisions.
Three Consumer Staples Stocks to Consider for a $1,000 Investment Amid Market Uncertainty
The Motley Fool identifies Church & Dwight, Keurig Dr Pepper, and Kenvue as consumer staples companies offering predictable demand for a $1,000 investment during uncertain markets. Church & Dwight beat first-quarter 2026 guidance with 5% organic sales growth driven entirely by volume, and it acquired Miss Mouth's Messy Eater for $325 million in May. Keurig Dr Pepper's stock is down nearly 29% from its 2025 peak despite beating revenue estimates for four straight quarters, while its energy drink portfolio including Ghost, C4, Venom, and Black Rifle Energy is expected to generate well over $1 billion in annual retail sales. Kenvue's skin health and beauty division grew 8.4% in the first quarter of 2026, and its pending merger with Kimberly-Clark is expected to close in the second half of the year, creating one of the largest consumer health and personal care platforms globally.
KDP · Demand · Neutral Stock down 29% from peak despite beating revenue estimates; energy drink portfolio expected to generate over $1B in retail sales, but overall impact mixed.
KVUE · Demand · Positive Skin health and beauty division grew 8.4% in Q1 2026; pending merger with Kimberly-Clark.
KMB · Capital · Positive Pending merger with Kenvue expected to close in H2 2026, creating a large consumer health platform.
Kenvue’s Pending $40 Billion Merger With Kimberly-Clark Creates a Near-$3 Per Share Arbitrage Opportunity
Kenvue, the consumer health spinoff from Johnson & Johnson, is trading around $18.32 per share, well below the $21.01 per share total consideration offered in its pending $40 billion mega-merger with Kimberly-Clark. The deal, already approved by shareholders of both companies but still subject to foreign regulatory approvals, would give Kenvue investors $3.50 in cash plus 0.14625 Kimberly-Clark shares for each Kenvue share held. The combined company expects to capture roughly $2.1 billion in run rate cost synergies by giving local markets full profit-and-loss ownership while leveraging Kimberly-Clark’s global supply chain. Kenvue, a Dividend King with 63 consecutive years of payout increases, currently yields 4.53% and owns iconic brands such as Tylenol, Listerine, Neutrogena, and Band-Aid, while its first-quarter revenue rose 4.5% year over year to $3.9 billion and earnings per share jumped 47% to $0.25.
KMB · Capital · Positive Kimberly-Clark is the acquirer in a $40B merger expected to generate $2.1B in cost synergies.
KVUE · Capital · Positive Kenvue shareholders receive $3.50 cash plus 0.14625 KMB shares per share, creating an arbitrage opportunity above current price.
USA
